Results 61 to 70 of about 874,981 (155)

Comparative Role of Anti-TNF Agents versus IL-12/23 Inhibitors in Inflammatory Bowel Disease: An Updated Review

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Treatments for Crohn's Disease (CD) and Ulcerative Colitis (UC), two conditions that fall under the umbrella of Inflammatory Bowel Disease (IBD), must be both safe and effective. This review compares the effectiveness and safety of anti-TNF agents and IL-
Xue Bin Leong, Chuan Zhe Tang, Chloe Zi Ying Lee, Zoe Ling Hui Lee, Thai Hau Koo   +4 more
doaj   +1 more source

The IL-23/IL-17 axis in Behçet’s syndrome pathogenesis: from immunological perspectives to therapeutic implications

Frontiers in Immunology
Behçet’s Syndrome (BS) is a systemic vasculitis characterized by variable vessel involvement and an elusive etiology, though immunogenetic studies strongly implicate the IL-23/IL-17 axis which bridges innate and adaptive immunity, orchestrating type 17 T-
Mohammad E. Naffaa, Mohammad E. Naffaa, Fadi Hassan, Fadi Hassan, Mahmud Omar, Mahmud Omar, Kerem Abacar, Dennis McGonagle   +7 more
doaj   +1 more source

Treatment with Targeted Therapy in Patients with Psoriatic Arthritis and Inadequate Response to Methotrexate: Proposal for a Rational Strategy

Rheumatology and Therapy
Introduction The therapeutic arsenal for psoriatic arthritis (PsA) is gradually being expanded, but the use of these targeted treatments must be optimal.
Philippe Goupille, Guillermo Carvajal Alegria, Frank Verhoeven, Daniel Wendling   +3 more
doaj   +1 more source

Exploratory Retrospective Assessment of Patients with Psoriasis Receiving Biological Therapy

Medicina
Background and Objectives: Biological therapies improve disease severity and quality of life in patients with psoriasis, but data on Romanian patients remain limited.
Andrada-Luciana Lazar, Sorana D. Bolboacă, Adrian-Lucian Baican, Corina-Iulia Baican, Sorina Dănescu, Elisabeta Candrea, Diana Valentina Câmpean, Paula Iluț, Ioana Semenescu, Adela-Viviana Sitar-Tăut, Romana Vulturar, Olga Hilda Orășan, Angela Cozma   +12 more
doaj   +1 more source

Risankizumab as an effective therapeutic option in severe psoriasis unsuccessfully treated with therapies involving anti- TNF-α and anti-IL-17

Przegląd Dermatologiczny, 2020
Michał Adamczyk, Dorota Krasowska
doaj   +1 more source

Targeting IL-23p19 in Inflammatory Bowel Disease: The Road Ahead

Journal of Inflammation Research
Erica Bartolotta,1,2 Giuseppe Privitera,1,3 Arianna Dal Buono,1,3 Roberto Gabbiadini,3 Laura Loy,3 Giulia Migliorisi,1,3 Cristina Bezzio,1,3 Alessandro Armuzzi1,31Gastroenterology and Digestive Endoscopy Unit, IRCCS Humanitas Research Hospital, Rozzano ...
Bartolotta E, Privitera G, Dal Buono A, Gabbiadini R, Loy L, Migliorisi G, Bezzio C, Armuzzi A   +7 more
doaj  

Anti-IL-23-antistoffer mot prostatakreft? [PDF]

Tidsskrift for Den norske legeforening, 2019
openaire   +1 more source

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab

Clinical, Cosmetic and Investigational Dermatology, 2017
Tiana Kazemi,1 Benjamin Farahnik,2 John Koo,3 Kourosh Beroukhim1 1University of California – Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2University of Vermont College of Medicine, Burlington, VT, 3University of California –
Kazemi T, Farahnik B, Koo J, Beroukhim K
doaj  

Go-ahead for first anti-IL-23 mAb to treat psoriasis [PDF]

Nature Biotechnology, 2017
openaire   +2 more sources

A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit. [PDF]

Immunity
Jiang R, Blauvelt A, Shi L, Tsoi LC, Bogle R, Fox J, Gharaee-Kermani M, Chen L, Zhang H, Xing X, Sarkar MK, Plazyo O, Kahlenberg JM, Billi AC, Matheson RT, Photowala H, Ehst BD, Gudjonsson JE.   +17 more
europepmc   +1 more source